

**REMARKS**


With entry of this amendment, claims 1-48 are pending. Claim 8 has been amended to be dependent upon claim 1. Claim 10 has been amended to be multiply dependent upon claims 1 and 8. Claim 17 has been amended to depend from Claim 15.

In response to the Restriction Requirement, applicants elect the peptide: Tyr-Gly-Phe-Gly-Gly, as denoted by SEQ ID NO: 1. Regarding the elected condition, applicant wishes to elect claims related to a method for enhancing mobilization of hematopoietic stem cells to the peripheral blood (claim 1) and the application of this method for the treatment of hematological disorders which include lymphomas, Leukemias, Hodgkin's disease and myeloproliferative disorders.

Early and favorable action on the application is respectfully solicited.

Respectfully submitted,

Date: June 29, 2006

  
Ann S. Hobbs, Ph.D.  
Registration No. 36,830  
VENABLE  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 344-4000  
Telefax: (202) 344-8300  
[ashobbs@venable.com](mailto:ashobbs@venable.com)